Noncarbapenems for the Treatment of Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Bacteria

C. Whitney White, PharmD, BCPS; Jeffrey A. Kyle, PharmD, BCPS; Crystal M. Deas, PharmD, BCPS; Jacob Campbell, PharmD


South Med J. 2019;112(8):438-443. 

In This Article


The results of this retrospective chart review conducted in a nonacademic institution are mostly consistent with those of other published studies and suggest that noncarbapenem antibiotics that show in vitro activity may be effective alternatives to carbapenems for ESBL UTIs in certain patient populations, although the higher rates of microbiological failures associated with certain noncarbapenems observed in this study may be cause for reservation. Prospective studies with larger sample sizes are needed to more fully assess safe and effective alternatives to carbapenems for the treatment of ESBL UTIs.